Tuebingen, Germany – Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced today that it has entered into a research collaboration and license agreement with Genmab A/S (Nasdaq Copenhagen: GEN) to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications.
Naarden, The Netherlands, and Munich, Germany – Forbion, a leading European life science venture capital firm, has today announced the first close of its fourth flagship fund Forbion IV, at EUR 270 million, exceeding the EUR 250 million target size.
Cambridge, UK and Melbourne, Australia – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed GMP manufacturing and bioconjugation agreements with Telix Pharmaceuticals Limited (‘Telix’). The agreements have a combined value of $5.9 million and these projects are expected to be substantially completed within a 15 month period.
Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, today announces that Igor Matushansky, MD, PhD, has been appointed as Non-Executive Director of the Company with immediate effect.
Cambridge, UK, - Abcam, a global innovator in life science reagents and tools today announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.
Birkerød, Denmark – Reapplix ApS, the regenerative medicine company, initially focussed on chronic wounds, announces that positive outcome data of an independent Randomized Controlled Trial (RCT) of its LeucoPatch® wound healing platform was presented at the American Diabetes Association 78th Scientific Sessions meeting in Orlando, Florida. The Company has also provided an update on the Company’s progress.
Los Angeles, CA,USA – Neural Analytics, Inc., a medical robotics company developing and commercializing technologies to measure and track brain health, announced today that it received CE Mark for its NeuralBot™ System, a robotic assistance technology which automatically adjusts orientation and position of its ultrasound products under the guidance of a healthcare professional. When used with its previously cleared Lucid™ M1 Transcranial Doppler Ultrasound System®, it can assist clinicians to non-invasively monitor a patient’s brain blood flow characteristics and can provide information to diagnose a variety of neurological disorders.
Accrington, UK – National Care Group (“NCG”), a leading provider of care and support services, announces the acquisition of the Shelton Care in Stoke-on-Trent. Financial details of the deal were not disclosed.
Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC). Financial details have not been disclosed.
Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, today announces that Eva-Lotta Allan has been appointed as Non-Executive Director of the Company with immediate effect.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an exclusive agreement with Lukare Medical (‘Lukare’) to manage the supply and distribution of Elliotts B® Solution.
Houston and London – Cell Medica (or ‘the Company’), a leader in next generation cellular immunotherapies for the treatment of cancer, today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.
Copenhagen, Denmark - Xellia Pharmaceuticals (‘Xellia’ or the ‘Company’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, announced today that it has further strengthened its leadership team by appointing Matthew Anderson as Chief Financial Officer (CFO) with immediate effect. He will be taking over from the current interim CFO, Otto Rasmussen.
London, Boston, Tokyo — Orphan drugs are forecast to remain one of the fastest growth areas of the global pharmaceutical market according to Evaluate’s annual industry report, the “EvaluatePharma World Preview 2018, Outlook to 2024”. The rare disease space is predicted to capture 20% of the total $1.2trn market in 2024. Supporting this growth are the launches of novel therapies, including gene and cell therapies, as well as increased access to medicines globally.
Cambridge, UK – Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD).
Vienna, Austria and Foster City, CA - Hookipa Biotech AG (“Hookipa”), a clinical-stage biotech company pioneering an innovative class of active immunization therapies for oncology and infectious diseases and Gilead Sciences, Inc., (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, today announced that they have entered into a research collaboration and license agreement that grants Gilead exclusive rights to Hookipa’s TheraT® and Vaxwave® arenavirus vector-based immunization technologies for two major chronic infectious disease indications, hepatitis B virus (HBV) and human immunodeficiency virus (HIV).
Sydney, Australia - Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), developing a new class of synthetic antibiotics, today said it had received formal guidance following its meeting last month with the US Food & Drug Administration’s Division of Anti-Infective Products, Office of Antimicrobial Products.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, notes the publication in Future Oncology of a peer reviewed article by expert physicians evaluating recent research and publications on dexrazoxane, marketed by Clinigen as Cardioxane®. The physicians concluded that dexrazoxane’s cardioprotectant benefits outweighed the risks for its use in children and adolescent cancer patients, which is consistent with the EC’s change of label approval in 2017.
Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has published its full year results for the year to 31 March 2018.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has signed a commercial agreement with Bristol-Myers Squibb (‘BMS’) in South Africa. The agreement covers BMS’ South African portfolio of products for an initial period of five years.
Cambridge, UK – F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies, announced today that its partner Denali Therapeutics (NASDAQ: DNLI) (Denali) has chosen to exercise early its option to acquire the asset-centric vehicle F-star Gamma Ltd (F-star Gamma).
Shanghai, and Cambridge, UK — Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, and Crescendo Biologics Ltd (Crescendo Biologics), the developer of multi-functional biologics, announced today an exclusive, worldwide licensing agreement under which Zai Lab will develop, commercialize, and manufacture a topical, innovative antibody VH domain therapeutic for potential application in inflammatory indications.
London, UK, Boston, US and Tokyo, Japan – Continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market, with sales predicted to grow at over 11% a year to $262bn by 2024, according to EvaluatePharma’s fifth Orphan Drug Report.